Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-617 in RB1-Negative Leiomyosarcoma
NCT07633756Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EXS617 in leiomyosarcoma (LMS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate and Adverse Events at 1 year. Started Oct 2026; status: recruiting.
02
Drugs
EXS617
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT07633756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633756.